OUR TEAM

Dreavent's team combines direct experience at the highest levels of pharmaceutical venture capital — from inside the corporate venture arms of the world's leading pharma companies to Tier 1 biotech funds — with deep translational science expertise and a strategic network built over decades at the center of Boston's life sciences ecosystem.

The Investment Committee has collectively built, evaluated, and exited assets across the full spectrum of biotech development. The Translational Unit brings the specific expertise required to connect Spanish science to global pharmaceutical demand. And Wendy Nelson's work building and leading the Boston Biotech Forums has created one of the most extensive networks of scientists, pharmaceutical executives, clinical institutions, and investors in the ecosystem.